Beigene Ltd Company Profile (NASDAQ:BGNE)

About Beigene Ltd (NASDAQ:BGNE)

Beigene Ltd logoBeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016. BGB-3111, BGB-290 and BGB-283 are its molecularly targeted agents and is its immuno-oncology agent. BGB-3111 is a potent and highly selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). BGB-283 is a molecule inhibitor of both the monomer and dimer forms of the RAF kinase. BGB-290 is a molecularly targeted, orally available, potent and highly selective inhibitor of the poly ADP ribose polymerase (PARP) family members. BGB-A317 is an investigational humanized monoclonal antibody against the immune checkpoint receptor, PD-1.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BGNE
  • CUSIP: N/A
  • Web: www.beigene.com
Capitalization:
  • Market Cap: $1.49 billion
  • Outstanding Shares: 39,725,000
Average Prices:
  • 50 Day Moving Avg: $38.27
  • 200 Day Moving Avg: $35.40
  • 52 Week Range: $24.53 - $42.09
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.56
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $393,000.00
  • Price / Sales: 3,782.47
  • Book Value: $7.76 per share
  • Price / Book: 4.82
Profitability:
  • EBIDTA: ($145,930,000.00)
  • Return on Equity: -79.29%
  • Return on Assets: -50.13%
Debt:
  • Debt-to-Equity Ratio: 0.10%
  • Current Ratio: 7.16%
  • Quick Ratio: 7.16%
Misc:
  • Average Volume: 101,609 shs.
  • Short Ratio: 11.85
 

Frequently Asked Questions for Beigene Ltd (NASDAQ:BGNE)

What is Beigene Ltd's stock symbol?

Beigene Ltd trades on the NASDAQ under the ticker symbol "BGNE."

How were Beigene Ltd's earnings last quarter?

Beigene Ltd (NASDAQ:BGNE) issued its quarterly earnings data on Wednesday, March, 22nd. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by $0.19. The company earned $1 million during the quarter, compared to analyst estimates of $3.75 million. The business's quarterly revenue was down 78.6% compared to the same quarter last year. During the same quarter last year, the business earned ($3.05) earnings per share. View Beigene Ltd's Earnings History.

Where is Beigene Ltd's stock going? Where will Beigene Ltd's stock price be in 2017?

2 equities research analysts have issued 12 month price targets for Beigene Ltd's shares. Their forecasts range from $52.00 to $52.00. On average, they expect Beigene Ltd's stock price to reach $52.00 in the next twelve months. View Analyst Ratings for Beigene Ltd.

What are analysts saying about Beigene Ltd stock?

Here are some recent quotes from research analysts about Beigene Ltd stock:

  • 1. Maxim Group analysts commented, "BeiGene reported 1Q17 results. The company spent $52.5M during the quarter. The increased operating expenses were driven by clinical expansion to pivotal studies. Net loss for the quarter was $50.6M or ($1.27) per share. BeiGene ended the period with $327M of liquidity on the balance sheet. We model rising R&D expenses with clinical advances." (5/11/2017)
  • 2. According to Zacks Investment Research, "BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. " (3/27/2017)
  • 3. Cowen and Company analysts commented, "BeiGene reported positive Phase I data in Waldenstrom’s Macroglobulinemia (WM) for." (10/7/2016)

Are investors shorting Beigene Ltd?

Beigene Ltd saw a increase in short interest in the month of April. As of April 13th, there was short interest totalling 1,248,501 shares, an increase of 3.9% from the March 31st total of 1,201,451 shares. Based on an average daily volume of 95,925 shares, the days-to-cover ratio is presently 13.0 days.

Who are some of Beigene Ltd's key competitors?

When did Beigene Ltd IPO?

(BGNE) raised $126 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

Who owns Beigene Ltd stock?

Beigene Ltd's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (11.18%), Wellington Management Group LLP (3.52%), Boxer Capital LLC (2.13%), Myriad Asset Management Ltd. (0.93%), RA Capital Management LLC (0.60%) and Fosun International Ltd (0.60%). Company insiders that own Beigene Ltd stock include Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, John Oyler, Ruirong Yuan, Thomas Malley and Xiaodong Wang. View Institutional Ownership Trends for Beigene Ltd.

Who sold Beigene Ltd stock? Who is selling Beigene Ltd stock?

Beigene Ltd's stock was sold by a variety of institutional investors in the last quarter, including Fosun International Ltd, Tekla Capital Management LLC, Bank of Montreal Can, TD Asset Management Inc. and Goldman Sachs Group Inc.. Company insiders that have sold Beigene Ltd stock in the last year include Donald W Glazer, John Oyler and Xiaodong Wang. View Insider Buying and Selling for Beigene Ltd.

Who bought Beigene Ltd stock? Who is buying Beigene Ltd stock?

Beigene Ltd's stock was acquired by a variety of institutional investors in the last quarter, including Myriad Asset Management Ltd., Wellington Management Group LLP, Ariose Capital Management Ltd, Candriam Luxembourg S.C.A., FMR LLC, Emory University, OppenheimerFunds Inc. and First Trust Advisors LP. Company insiders that have bought Beigene Ltd stock in the last two years include Bros Advisors Lp Baker, Howard Liang, Ruirong Yuan and Thomas Malley. View Insider Buying and Selling for Beigene Ltd.

How do I buy Beigene Ltd stock?

Shares of Beigene Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Beigene Ltd stock cost?

One share of Beigene Ltd stock can currently be purchased for approximately $37.42.

Analyst Ratings

Consensus Ratings for Beigene Ltd (NASDAQ:BGNE) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $52.00 (38.96% upside)

Analysts' Ratings History for Beigene Ltd (NASDAQ:BGNE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/11/2017Maxim GroupReiterated RatingBuy$52.00HighView Rating Details
10/7/2016Cowen and CompanyReiterated RatingBuyN/AView Rating Details
4/8/2016Morgan StanleyBoost Price Target$39.00 -> $42.00N/AView Rating Details
2/29/2016Robert W. BairdInitiated CoverageOutperform$44.00N/AView Rating Details
2/29/2016Goldman Sachs Group IncInitiated CoverageBuy$33.00N/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for Beigene Ltd (NASDAQ:BGNE)
Earnings by Quarter for Beigene Ltd (NASDAQ:BGNE)
Earnings History by Quarter for Beigene Ltd (NASDAQ:BGNE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/22/2017Q4($0.86)($1.05)$3.75 million$1.00 millionViewN/AView Earnings Details
11/10/2016Q316($0.78)($1.08)$1.88 millionViewN/AView Earnings Details
8/10/2016Q2($0.68)($0.73)$2.08 million$0.40 millionViewN/AView Earnings Details
5/11/2016Q1($0.05)($0.97)$0.70 millionViewN/AView Earnings Details
3/30/2016Q4($1.06)($3.05)$1.74 million$4.68 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Beigene Ltd (NASDAQ:BGNE)
Current Year EPS Consensus Estimate: $-5.00 EPS
Next Year EPS Consensus Estimate: $-4.37 EPS

Dividends

Dividend History for Beigene Ltd (NASDAQ:BGNE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Beigene Ltd (NASDAQ:BGNE)
Institutional Ownership Percentage: 33.01%
Insider Trades by Quarter for Beigene Ltd (NASDAQ:BGNE)
Institutional Ownership by Quarter for Beigene Ltd (NASDAQ:BGNE)
Insider Trades by Quarter for Beigene Ltd (NASDAQ:BGNE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/4/2017Xiaodong WangDirectorSell14,461$40.80$590,008.80View SEC Filing  
5/1/2017John OylerCEOSell36,149$40.47$1,462,950.03View SEC Filing  
4/5/2017Xiaodong WangDirectorSell11,650$36.83$429,069.50View SEC Filing  
3/24/2017Xiaodong WangDirectorSell38,107$36.96$1,408,434.72View SEC Filing  
3/20/2017John OylerCEOSell31,989$39.39$1,260,046.71View SEC Filing  
3/10/2017Xiaodong WangDirectorSell36,892$39.89$1,471,621.88View SEC Filing  
3/6/2017John OylerCEOSell108,999$40.91$4,459,149.09View SEC Filing  
2/27/2017Xiaodong WangDirectorSell38,351$38.19$1,464,624.69View SEC Filing  
2/21/2017John OylerCEOSell64,963$40.55$2,634,249.65View SEC Filing  
11/23/2016Thomas MalleyDirectorBuy30,000$32.00$960,000.00View SEC Filing  
11/18/2016Bros. Advisors Lp BakerDirectorBuy1,760,495$32.00$56,335,840.00View SEC Filing  
9/28/2016Donald W GlazerDirectorSell41,463$30.66$1,271,255.58View SEC Filing  
9/27/2016Donald W GlazerDirectorSell47,149$29.61$1,396,081.89View SEC Filing  
9/23/2016Donald W GlazerDirectorSell36,443$31.02$1,130,461.86View SEC Filing  
9/21/2016Donald W GlazerDirectorSell67,252$31.42$2,113,057.84View SEC Filing  
2/8/2016Bros. Advisors Lp BakerDirectorBuy1,912,680$24.00$45,904,320.00View SEC Filing  
2/8/2016Howard LiangCFOBuy65,000$1.85$120,250.00View SEC Filing  
2/8/2016Ruirong YuanInsiderBuy130,000$1.85$240,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Beigene Ltd (NASDAQ:BGNE)
Latest Headlines for Beigene Ltd (NASDAQ:BGNE)
Source:
DateHeadline
finance.yahoo.com logoBeiGene to Present at the 2017 UBS Global Healthcare Conference
finance.yahoo.com - May 17 at 8:56 PM
americanbankingnews.com logoBeigene Ltd (BGNE) Given Buy Rating at Maxim Group
www.americanbankingnews.com - May 13 at 11:56 PM
finance.yahoo.com logoBeiGene Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 10 at 11:56 PM
americanbankingnews.com logoBeigene Ltd (BGNE) Expected to Announce Earnings of -$0.97 Per Share
www.americanbankingnews.com - May 10 at 8:18 AM
americanbankingnews.com logoBeigene Ltd (BGNE) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - May 6 at 12:16 AM
americanbankingnews.com logoBeigene Ltd (BGNE) to Release Earnings on Monday
www.americanbankingnews.com - May 5 at 11:54 PM
americanbankingnews.com logoBeigene Ltd (BGNE) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - May 5 at 11:31 PM
americanbankingnews.com logoBeigene Ltd (BGNE) Director Xiaodong Wang Sells 14,461 Shares
www.americanbankingnews.com - May 5 at 8:11 PM
americanbankingnews.com logoInsider Selling: Beigene Ltd (BGNE) CEO Sells 36,149 Shares of Stock
www.americanbankingnews.com - May 1 at 11:30 PM
americanbankingnews.com logoShort Interest in Beigene Ltd (BGNE) Expands By 3.9%
www.americanbankingnews.com - April 27 at 12:10 PM
finance.yahoo.com logoETFs with exposure to BeiGene Ltd. : April 26, 2017
finance.yahoo.com - April 26 at 3:20 PM
streetinsider.com logoBeiGene (BGNE) Say Phase I Study of PD-1 Antibody BGB-A317 in Combination with PARP Inhibitor BGB-290 to be Presented at ASCO
www.streetinsider.com - April 22 at 3:49 PM
americanbankingnews.com logoBeigene Ltd (BGNE) Given a $52.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - April 21 at 6:16 PM
finance.yahoo.com logoBeiGene Announces Presentation on a Phase I Study of PD-1 Antibody BGB-A317 in Combination with PARP …
finance.yahoo.com - April 21 at 3:58 PM
finance.yahoo.com logoBeiGene Announces Initiation of First Pivotal Study in China of PD-1 Antibody BGB-A317
finance.yahoo.com - April 21 at 3:58 PM
finance.yahoo.com logoBeiGene Announces Presentation on a Phase I Study of PD-1 Antibody BGB-A317 in Combination with PARP Inhibitor BGB-290 at the 2017 American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - April 21 at 3:58 PM
americanbankingnews.com logoBeigene Ltd (BGNE) Expected to Post Earnings of -$0.97 Per Share
www.americanbankingnews.com - April 19 at 7:34 AM
americanbankingnews.com logoBeigene Ltd (BGNE) Director Sells $429,069.50 in Stock
www.americanbankingnews.com - April 7 at 7:59 PM
americanbankingnews.com logoBeigene Ltd (BGNE) Given a $52.00 Price Target at Maxim Group
www.americanbankingnews.com - April 3 at 5:07 PM
finance.yahoo.com logoBeiGene Presents Phase IB Data on RAF Dimer Inhibitor BGB-283 at the 2017 American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 2 at 3:48 PM
americanbankingnews.com logoBeigene Ltd (BGNE) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - March 27 at 8:58 PM
americanbankingnews.com logoBeigene Ltd (BGNE) Director Sells $1,408,434.72 in Stock
www.americanbankingnews.com - March 24 at 10:16 PM
finance.yahoo.com logoBeiGene Reports Fourth Quarter and Full Year 2016 Financial Results
finance.yahoo.com - March 22 at 8:36 PM
americanbankingnews.com logoJohn Oyler Sells 31,989 Shares of Beigene Ltd (BGNE) Stock
www.americanbankingnews.com - March 20 at 10:28 PM
americanbankingnews.com logoBeigene Ltd (BGNE) PT Set at $52.00 by Maxim Group
www.americanbankingnews.com - March 12 at 9:27 PM
us.rd.yahoo.com logoBeiGene Announces Initiation of Pivotal Study in China with BTK Inhibitor BGB-3111 in Patients with Relapsed or Refractory CLL/SLL
us.rd.yahoo.com - March 9 at 4:29 PM
seekingalpha.com logoBeiGene to build biologics manufacturing facility in Guangzhou
seekingalpha.com - March 8 at 1:57 AM
finance.yahoo.com logoBeiGene and Guangzhou Development District Establish Joint Venture to Build Biologics Manufacturing Facility
finance.yahoo.com - March 7 at 11:01 AM
finance.yahoo.com logo7:06 am BeiGene forms JV w/ its affiliate Guangzhou GET Technology Development to establish a biologics manufacturing facility in Guangzhou, China
finance.yahoo.com - March 7 at 11:01 AM
biz.yahoo.com logoBEIGENE, LTD. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligati
biz.yahoo.com - March 7 at 11:01 AM
finance.yahoo.com logoBeiGene Announces Presentation of Phase IB Data on BGB-283 at the 2017 American Association for Cancer Research Annual Meeting
finance.yahoo.com - March 2 at 3:19 PM
finance.yahoo.com logoBeiGene Announces Initiation of First Pivotal Study in China with BTK Inhibitor BGB-3111
finance.yahoo.com - March 2 at 3:19 PM
finance.yahoo.com logoBeiGene to Present at the Cowen and Company 37th Annual Health Care Conference
finance.yahoo.com - February 28 at 6:07 AM
finance.yahoo.com logoBeiGene to Participate in the LEERINK Partners 6th Annual Global Healthcare Conference
finance.yahoo.com - February 8 at 8:34 PM
streetinsider.com logoBeiGene (BGNE) Initiates Global Phase III Trial of BTK Inhibitor BGB-3111 in WM
www.streetinsider.com - January 26 at 1:23 AM
us.rd.yahoo.com logoBeiGene Initiates Global Phase III Trial of the BTK Inhibitor BGB-3111 in Waldenström’s Macroglobulinemia
us.rd.yahoo.com - January 25 at 8:21 PM
streetinsider.com logoBeiGene (BGNE) Doses First Patient in China Phase I Trial of BGB-A317
www.streetinsider.com - December 30 at 4:13 PM
streetinsider.com logoBeiGene (BGNE) Doses First Patient in China with BGB-290 in Phase I Trial
www.streetinsider.com - December 22 at 1:32 AM
finance.yahoo.com logoBeiGene (BGNE): Strong Industry, Solid Earnings Estimate Revisions
finance.yahoo.com - December 12 at 9:48 AM
finance.yahoo.com logoCancer Genetics, Inc. Is Selected by BeiGene, Ltd. to Collaborate on Clinical Trial Services & Advance Portfolio of Novel Oncology Therapeutics
finance.yahoo.com - December 7 at 4:30 PM
streetinsider.com logoBeiGene (BGNE) Presents Updated BGB-3111 Phase 1 Data in CLL/SLL; Strong ORR and PFS Noted
www.streetinsider.com - December 6 at 3:20 PM
finance.yahoo.com logoBeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Waldenström’s Macroglobulinemia …
finance.yahoo.com - December 6 at 3:20 PM
us.rd.yahoo.com logoBeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Waldenström’s Macroglobulinemia at the 2016 American Society of Hematology Annual Meeting
us.rd.yahoo.com - December 6 at 5:10 AM
us.rd.yahoo.com logoBeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia at the 2016 American Society of Hematology Annual Meeting
us.rd.yahoo.com - December 5 at 3:15 PM
us.rd.yahoo.com logo11:16 am BeiGene presents updated clinical data on BTK Inhibitor BGB-3111 in patients with chronic lymphocytic leukemia and small lymphocytic leukemia at the 2016 American Society of Hematology Annual Meeting
us.rd.yahoo.com - December 5 at 3:15 PM
finance.yahoo.com logoBEIGENE, LTD. Financials
finance.yahoo.com - November 18 at 3:49 PM
finance.yahoo.com logoBeiGene Announces Pricing of $200 Million Public Offering
finance.yahoo.com - November 17 at 8:26 PM
finance.yahoo.com logoBeiGene Prices Secondary Offering
finance.yahoo.com - November 17 at 1:27 PM
finance.yahoo.com logoBeiGene Announces Proposed Public Offering
finance.yahoo.com - November 16 at 9:00 PM
biz.yahoo.com logoBEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - November 14 at 8:37 AM

Social

Chart

Beigene Ltd (BGNE) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff